[1]
|
Siegel, R.L., Miller, K.D. and Jemal, A. (2018) Cancer Statistics, 2018. CA: A Cancer Journal for Clinicians, 68, 7-30.
https://doi.org/10.3322/caac.21442
|
[2]
|
Folkman, J. (1971) Tumor Angiogenesis: Therapeutic Implications. New England Journal of Medicine, 285, 1182-1186. https://doi.org/10.1056/NEJM197111182852108
|
[3]
|
Monk, B.J., Sill, M.W., Burger, R.A., et al. (2009) Phase II Trial of Bevacizumab in the Treatment of Persistent or Recurrent Squamous Cell Carcinoma of the Cervix: A Gynecologic Oncology Group Study. Journal of Clinical Oncology, 27, 1069-1074. https://doi.org/10.1200/JCO.2008.18.9043
|
[4]
|
Monk, B.J., Mas, L.L., Zarba, J.J., et al. (2010) Phase II, Open-Label Study of Pazopanib or Lapatinib Monotherapy Compared with Pazopanib Plus Lapatinib Combination Therapy in Patients with Advanced and Recurrent Cervical Cancer. Journal of Clinical Oncology, 28, 3562-3569. https://doi.org/10.1200/JCO.2009.26.9571
|
[5]
|
Tewari, K.S., Sill, M.W., Penson, R.T., et al. (2017) Bevacizumab for Advanced Cervical Cancer: Final Overall Survival and Adverse Event Analysis of a Randomised, Controlled, Open-Label, Phase 3 Trial (Gynecologic Oncology Group 240). Lancet, 390, 1654-1663. https://doi.org/10.1016/S0140-6736(17)31607-0
|
[6]
|
Tewari, K.S., Sill, M.W., Long, H.R., et al. (2014) Improved Survival with Bevacizumab in Advanced Cervical Cancer. New England Journal of Medicine, 370, 734-743. https://doi.org/10.1056/NEJMoa1309748
|
[7]
|
Moore, D.H., Tian, C., Monk, B.J., et al. (2010) Prognostic Factors for Response to Cisplatin-Based Chemotherapy in Advanced Cervical Carcinoma: A Gynecologic Oncology Group Study. Gynecologic Oncology, 116, 44-49.
https://doi.org/10.1016/j.ygyno.2009.09.006
|
[8]
|
Penson, R.T., Huang, H.Q., Wenzel, L.B., et al. (2015) Bevacizumab for Advanced Cervical Cancer: Patient-Reported Outcomes of a Randomised, Phase 3 Trial (NRG Oncology-Gynecologic Oncology Group Protocol 240). Lancet Oncology, 16, 301-311. https://doi.org/10.1016/S1470-2045(15)70004-5
|
[9]
|
Pim, D., Collins, M. and Banks, L. (1992) Human Papillomavirus Type 16 E5 Gene Stimulates the Transforming Activity of the Epidermal Growth Factor Receptor. Oncogene, 7, 27-32.
|
[10]
|
Mezache, L., Paniccia, B., Nyinawabera, A., et al. (2015) Enhanced Expression of PD L1 in Cervical In-traepithelial Neoplasia and Cervical Cancers. Modern Pathology, 28, 1594-1602. https://doi.org/10.1038/modpathol.2015.108
|
[11]
|
Feng, Y.C., Ji, W.L., Yue, N., Huang, Y.C. and Ma, X.M. (2018) The Relationship between the PD-1/PD-L1 Pathway and DNA Mismatch Repair in Cervical Cancer and Its Clin-ical Significance. Cancer Management and Research, 10, 105-113. https://doi.org/10.2147/CMAR.S152232
|
[12]
|
Reddy, O.L., Shintaku, P.I. and Moatamed, N.A. (2017) Programmed Death-Ligand 1 (PD-L1) Is Expressed in a Significant Number of the Uterine Cervical Carcinomas. Diagnostic Pathology, 12, Article No. 45.
https://doi.org/10.1186/s13000-017-0631-6
|
[13]
|
Naumann, R.W., Hollebecque, A., Meyer, T., et al. (2019) Safety and Efficacy of Nivolumab Monotherapy in Recurrent or Metastatic Cervical, Vaginal, or Vulvar Carcinoma: Results from the Phase I/II CheckMate 358 Trial. Journal of Clinical Oncology, 37, 2825-2834. https://doi.org/10.1200/JCO.19.00739
|
[14]
|
Frenel, J.S., Le Tourneau, C., O’Neil, B., et al. (2017) Safety and Efficacy of Pembrolizumab in Advanced, Programmed Death Ligand 1-Positive Cervical Cancer: Results from the Phase Ib KEYNOTE-028 Trial. Journal of Clinical Oncology, 35, 4035-4041. https://doi.org/10.1200/JCO.2017.74.5471
|
[15]
|
Chung, H.C., Ros, W., Delord, J.P., et al. (2019) Efficacy and Safety of Pembrolizumab in Previously Treated Advanced Cervical Cancer: Results from the Phase II KEYNOTE-158 Study. Journal of Clinical Oncology, 37, 1470-1478.
https://doi.org/10.1200/JCO.18.01265
|
[16]
|
Peng, Z., Wang, Q., Zhang, Y., et al. (2016) EBP50 Interacts with EGFR and Regulates EGFR Signaling to Affect the Prognosis of Cervical Cancer Patients. International Journal of Oncology, 49, 1737-1745.
https://doi.org/10.3892/ijo.2016.3655
|
[17]
|
Qin, Y., Ekmekcioglu, S., Forget, M.A., Szekvolgyi, L., Hwu, P., Grimm, E.A., et al. (2017) Cervical Cancer Neoantigen Landscape and Immune Activity Is Associated with Human Pap-illomavirus Master Regulators. Frontiers in Immunology, 8, Article No. 689. https://doi.org/10.3389/fimmu.2017.00689
|
[18]
|
Yang, W., Lu, Y.P., Yang, Y.Z., Kang, J.-R., Jin, Y.-D. and Wang, H.-W. (2017) Expressions of Programmed Death (PD)-1 and PD-1 Ligand (PD-L1) in Cervical Intraepithelial Neoplasia and Cervical Squamous Cell Carcinomas Are of Prognostic Value and Associated With Human Papillomavirus Status. Journal of Obstetrics and Gynaecology Research, 43, 1602-1612. https://doi.org/10.1111/jog.13411
|
[19]
|
Heeren, A.M., Punt, S., Bleeker, M.C., et al. (2016) Prognostic Effect of Different PD-L1 Expression Patterns in Squamous Cell Carcinoma and Adenocarcinoma of the Cervix. Modern Pathology, 29, 753-763.
https://doi.org/10.1038/modpathol.2016.64
|
[20]
|
Curie, I. (2017) Nivolumab in Association with Radiotherapy and Cisplatin in Locally Advanced Cervical Cancers Followed by Adjuvant Nivolumab for up to 6 Months. NCT03298893.
|
[21]
|
NCI (National Cancer Institute) (2018) Atezolizumab before and/or with Chemoradiotherapy in Immune System Activation in Patients with Node Positive Stage IB2, II, IIIB, or IVA Cervical Cancer. NCT03738228.
|
[22]
|
Trust RMNF (2017) A Study of Pembrolizumab And Platinum with Radiotherapy in Cervix Cancer. NCT03144466.
|